Current Trials

PLANet 2.0 – AHCC12 and AHCC13

AHCC12 & AHCC13

Precision Medicine in Liver Cancer across an Asia Pacific Network 2.0 (PLANet 2.0) (NCT05516628)

AHCC12:

Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab plus Bevacizumab in Resected Hepatocellular Carcinoma (HCC)(EMPHASIS)(NCT05516628)

AHCC13:

Liquid Biopsy based Identification of Predictive Biomarkers of Response in Intermediate/Locally Advanced HCC receiving Y90 +/- Atezolizumab plus Bevacizumab (NCT05377034)
Status

Recruiting
Contributing Principal Investigators and Centres

Singapore

Adrian Chiow (Changi General Hospital), Toh Han Chong (National Cancer Centre), Chee Cheng Ean (National University Hospital), Kam Juinn Huar (Sengkang General Hospital), Brian Goh (Singapore General Hospital), samol jens (Tan Tock Seng Hospital)

Up to 11 overseas sites in Asia-Pacific
Thematic Principal Investigators

Theme 1: Deep Phenotyping and Correlation with Clinical Responses to Therapy

Name: Pierce Chow
Designation: Senior Consultant
Institution: National Cancer Centre

Name: Patrick Tan
Designation: Executive Director
Institution: A*STAR Genome Institute of Singapore

Theme 2: Elucidating Spatial Distribution of Biomarkers at Single-cell Resolution

Name: Vinay Tergaonkar
Designation: Research Director
Institution: A*STAR Institute of Molecular and Cell Biology

Theme 3: Translational and Functional Immunomics

Name: Toh Han Chong
Designation: Senior Consultant
Institution: Division of Medical Oncology, National Cancer Centre

Theme 4: Pre-Clinical Disease Modelling and Target Discovery

Name: Tam Wai Leong
Designation: Senior Research Scientist
Institution: A*STAR Genome Institute of Singapore

Name: Edward Chow
Designation: Associate Director and Principal Investigator
Institution: Cancer Science Institute

Theme 5: Data Architecture, Data Security and Data Science Applications

Name: Roger Vaughan
Designation: Director
Institution: Centre for Quantitative Medicine, Duke-NUS Medical School
Protocol Chair

Pierce Chow
pierce.chow@duke-nus.edu.sg

AHCC11

Prospective Cohort Study of Changes in Circulatory micro-RNA after Surgical Resection of Hepatocellular Carcinoma (PROSECT)
Status

Recruiting
Contributing Principal
Investigators and Centres

 

Singapore

Adrian Chiow (Changi General Hospital), Pierce Chow (National Cancer Centre), Glenn Bonney (National University Hospital), Brian Goh (Singapore General Hospital), Kam Juinn Huar (Sengkang General Hospital), Vishalkumar G. Shelat (Tan Tock Seng Hospital)
Protocol Chair

Pierce Chow 
pierce.chow@duke-nus.edu.sg

AHCC10

Early Detection of Hepatocellular Carcinoma: miRNA, microbiome and imaging biomarkers in the evolution of chronic liver disease in a high-risk prospective cohort (ELEGANCE) (NCT04965259)
Status

Recruiting
Contributing Principal
Investigators and Centres

 

Singapore

Eugene Wong Yu Jun (Changi General Hospital), Toh Han Chong (National Cancer Centre), Lee Guan Huei (National University Hospital), Jason Chang (Singapore General Hospital), Chong Oi Fong (SingHealth Polyclinics – Bedok), Sabrina Wee (SingHealth Polyclinics – Bukit Merah), Tan Kee Tung (SingHealth Polyclinics – Marine Parade), Ong Kok Kiong (SingHealth Polyclinics – Outram), Tan Ngiap Chuan (SingHealth Polyclinics – Pasir Ris), Yeap Xin Yi (SingHealth Polyclinics – Punggol), Choo Han Jun (SingHealth Polyclinics – Sengkang), Sulaiha Binte Ithnin (SingHealth Polyclinics – Tampines), Marianne De Roza (Sengkang General Hospital), Yang Wei Lyn (Tan Tock Seng Hospital)
Protocol Chair

Pierce Chow 
pierce.chow@duke-nus.edu.sg

AHCC09

A multi-national, double-blind, placebo-controlled, parallel randomized arms, phase II trial to compare the safety and efficacy of SIRT-Y90 followed by atezolizumab plus bevacizumab versus SIRT-Y90 followed by placebo in patients with locally advanced hepatocellular carcinoma (HCC) (STRATUM) (NCT05377034)
Status

Recruiting
Contributing Principal Investigators and Centres

Singapore

Pierce Chow (National Cancer Centre), Toh Han Chong (National Cancer Centre), Chee Cheng Ean (National University Hospital)

up to 11 overseas sites from:

Taiwan (TBC)

South Korea (TBC)

China (TBC)
Protocol Chair

Pierce Chow
pierce.chow@duke-nus.edu.sg